Moore Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Moore Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-334,250	Closed	-$8.38M	–	830
2022 Q1	$8.38M	Buy	334,250 +13,050	+4%	+$367K	0.21%	95
2021 Q4	$11.7M	Buy	+321,200	New	+$11.3M	0.23%	87

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Moore Capital Management's CCXI Position: Q2 2022 in Review

Moore Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q2 2022, closing a stake of 334,250 shares — an estimated $8.38M sold.

Moore Capital Management first reported a position in CCXI in Q4 2021 and held it in 2 quarters. The position peaked at $11.7M in Q4 2021. 182 funds tracked by Wall St. Rank hold CCXI as of Q2 2022.

Moore Capital Management reported no remaining ChemoCentryx, Inc. position as of Q2 2022 after selling out during the quarter.
Moore Capital Management sold 334,250 ChemoCentryx, Inc. shares in Q2 2022, an estimated $8.38M.
Moore Capital Management first reported a position in ChemoCentryx, Inc. in Q4 2021 and held it in 2 quarters.
Moore Capital Management's ChemoCentryx, Inc. position peaked at $11.7M in Q4 2021.
182 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2022.

Based on Moore Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.